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Abstract  
 
The ability to monitor changes in the ionic composition of the extracellular environment is crucial 
to all living organisms. The discovery of the extracellular calcium-sensing receptor, CaSR, from 
mammalian parathyroid glands is the first example of this kind of mechanism and demonstrates 
how cells can detect small variations from physiological free ionized calcium in the extracellular 
fluids and evoke biological responses by altering the secretion of parathormone, PTH, acting on its 
target tissues, kidney, intestine and bone. Accordingly, aberrant calcium-sensing by the 
parathyroid glands due to altered CaSR expression or function is associated with impaired divalent 
cation homeostasis. CaSR activators, termed calcimimetics, have been developed to rectify 
hyperparathyroidism of various nature while drugs directed against the CaSR, or calcilytics, are in 
development for hypercalciuric disorders. The kidney also expresses a CaSR and recent evidence 
suggests that the renal CaSR directly contributes to the regulation of many aspects of kidney 
function in a PTH-independent manner. This review will focus on the direct roles of the CaSR in the 
kidney and on the potential impact of pharmacological CaSR modulators on the renal CaSR. 
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Introduction 
Parathyroid hormone (PTH) is the major determinant of serum calcium ion levels (Ca). Serum PTH 
levels are inversely related to those of Ca, with decreases in Ca promoting PTH release and direct 
Ca reabsorption from the kidney, Ca absorption from the intestine (by promoting the 1-
hydroxylation of 25(OH)D3 into 1,25(OH)2D3 by the kidney proximal tubule), and Ca resorption 
from the bone while increases in serum Ca cause opposite effects. Crucial to this process is the 
extracellular calcium-sensing receptor, CaSR,  located in the parathyroid glands1, which is able to 
detect and respond to even the smallest changes in serum Ca levels with alterations in PTH 
secretion. Excessive or defective Ca sensing by the parathyroid glands, either because of genetic or 
acquired mutations in the CaSR, results in altered divalent cation homeostasis, which can lead to 
significant, long-lasting morbidity if left untreated2. Thus, pharmacologial CaSR modulators have 
been developed to correct hyperparathyroid or hypoparathyroid disorders of various nature. 
Calcimimetic drugs have been developed to rectify abnormal CaSR expression or function and 
have been successfully employed for over a decade to treat hyperparathyroidism secondary to 
kidney failure3. Recently AMG416, a long-acting peptide CaSR agonist suitable for intravenous 
administration, is being evaluated in Phase 2 clinical trials in patients with secondary 
hyperparathyroidism receiving haemodialysis4. On the other hand, CaSR antagonists, termed 
calcilytics, are currently being investigated for the treatment of autosomal dominant 
hypocalcemia with hypercalciuria due to activating CaSR mutations 5 . 
The kidney plays a major role in the control of extracellular Ca and urinary Ca excretion is 
proportional to the filtered Ca load. For instance, increasing serum Ca results in an increase in 
urinary Ca excretion, an effect which can be observed in the absence of the Ca-regulating 
hormones, PTH and 1,25(OH)2D3. A number of observations have demonstrated that the kidney is 
a calcium-sensing organ owing to its ability to sense changes in both urine and serum Ca and a 
direct role for the CaSR has been proposed in renal calcium handling. For instance, familial 
hypocalciuric hypercalcemia is an autosomal dominant disease due to inactivating mutations of 
the CaSR gene and manifests with hypercalcemia, parathyroid hyperplasia and inappropriately 
normal or even low urinary Ca in the face of hypercalcemia.  
unusually low Ca:creatinine clearance ratio6. In a seminal study which preceded the molecular 
identification of the CaSR Attie and colleagues investigated the effects of PTH on urinary Ca 
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excretion in FHH patients with surgical hypoparathyroidism and compared their response to that 
seen in hypoparathyroid control patients. The authors firstly discovered that Ca clearance in FHH 
subjects was lower that control subjects upon intravenous calcium infusion. This difference was 
retained in the presence of acetazolamide, a diuretic which inhibits carbonic anhydrase in the 
proximal tubule and elsewhere but was completely abolished when the loop diuretic, ethacrinic 
acid, was administered, with greater calciuric response in FHH than control subjects. The authors 
therefore concluded that the thick ascending limb of Henle’s loop, TAL, is the major site for 
abnormal Ca transport in FHH patients7. Recently Loupy et al have investigated the impact of 
acute and chronic CaSR inhibition on serum Ca in thyroparathyroidectomised rats in the presence 
or absence of PTH infusion and shown that the CaSR directly participates to the control of 
extracellular Ca via the regulation of the paracellular Ca transport the by the TAL8. More recently 
evidence suggests that CaSR directly regulates Ca and Mg permeability via its actions on several 
tight junction proteins called claudins (Cldn) including  Cldn-149, 10, -16 and -1911 (see below). 
In addition to the TAL, Ca sensitivity has also been reported in a variety of cells from the proximal 
tubule to the collecting duct and juxtaglomerular apparatus12. The combined use of detection 
methods with enhanced sensitivity, of pharmacological CaSR modulators and of tissue-specific 
gene ablation studies have significantly enhanced our understanding of the role of the CaSR in the 
kidney. This review article will address the intrarenal distribution of the CaSR, the potential roles 
of this receptor in the kidney and of the implications of the use of pharmacological modulators on 
renal function. The hypothesis that the CaSR might mediate the sensitivity of cyclic adenosine 
monophosphate (cAMP)-linked hormones to type VI adenylyl cyclase (AC6) is also being discussed. 
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CaSR expression in the kidney 
Determination of the exact intrarenal distribution of the CaSR is crucial to our understanding of 
receptor’s functional role in this organ, but has been thus far controversial and hindered by the 
lack of suitably sensitive methods required for detecting low CaSR expression levels. Thus, while 
CaSR expression in cells of the parathyroid glands or the kidney TAL is unrefuted, CaSR expression 
in other tubular and glomerular cells of the kidney has been the object of significant debate. 
Inconsistent findings have been ascribed to species differences, to alternative methodological 
approaches or molecular tools employed. Recently Graca et al have used immunohistochemistry 
using commercially available and custom-made antibodies, directed against the amino- and 
carboxy-termini of the CaSR, as well against the whole fusion protein to investigate the intrarenal 
distribution of this receptor across human, rat and mouse kidney to enable the full physiological 
characterisation of the renal CaSR13. In addition, the authors employed the most sensitive and 
specific detection methods currently available that also provide information concerning the exact 
cellular localization of the CaSR mRNA and protein (namely branched DNA in situ hybridisation and 
proximity ligation assay, respectively). The key findings of this study are summarised in Table 1. 
These results show that the CaSR is expressed all along the nephron with, as expected, the highest 
expression within the TAL. CaSR expression was found in the cells of the collecting duct (CD) but 
with differences in the strenght of the immunoreactivity signal and in the cellular polarity (apical, 
basolateral or intracellular). This study also shows that intrarenal CaSR protein expression could 
not be detected in mice with targeted CaSR ablation from the kidney tubules. Proximity ligation 
assay confirmed CaSR expression within the glomerulus and the proximal tubule (PT), previously 
two sites of major controversies. This expression pattern was confirmed across species albeit 
significant variation in the overall expression levels and in the biochemical species expressed 
(CaSR monomer vs dimer) could be observed. These observations clarify the intrarenal distribution 
of the CaSR, which will not only allow for further elucidation of the role of the CaSR in the kidney 
but also inform on the potential therapeutic use, and effects, of pharmacological CaSR modulators 
in these regions.  
 
CaSR in the glomerulus and juxtaglomerular apparatus (JGA) 
CaSR expression in the glomerulus has been previously reported with inconsistent findings14, 15. 
Proximity ligation assay demonstrated low but above background CaSR expression in mouse, rat 
and human glomeruli, in both podocytes and mesangial cells13. Intriguingly, the study by Graca et 
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al points to significant differences in the expression levels which can be observed even within 
adjacent glomeruli of the same kidney and that could be ascribed to differences in the functional 
status of the cells13. This observation, together with the very low CaSR expression levels, could 
account for some of the discrepant reports of receptor expression in the glomerulus. 
Evidence for a role for the CaSR in the regulation of glomerular function has derived from studies 
in wich glomerular damage was induced in vitro and in vivo  by the toxin puromycin 
aminonucleoside (PAN) 16. These studies show that the CaSR is expressed in murine podocytes 
where calcimimetics prevent PAN-induced apoptosis and cytoskeletal damage in vitro16. In 
addition, calcimimetic treatment also prevented PAN-induced proteinuria and glomerulosclerosis 
in rats in vivo16. Calcimimetics also decreased the progression  of renal damage by preventing 
podocyte loss and interstitial fibrosis in uninephrectomised, apolipoprotein E-deficient mice17. The 
calcimimetic effects were observed in the absence of either serum PTH or systemic blood pressure 
changes suggesting a direct involvement of the glomerular CaSR.  
In human cultured mesangial cells, CaSR activation leads to intracellular Ca mobilisation by both 
Gq-linked activation of inositol trisphosphate and extracellular Ca influx via TRPC3/6 channels15. 
Aberrant Gq signalling causes glomerular damage via activation of TRPC6 in a murine PAN 
nephrosis and of diabetic nephropathy18 but whether direct CaSR activation in mesangial cells 
negatively impacts on glomerular function via Gq-linked opening of TRPC6 is unknown. Thus, 
further studies are necessary to investigate the existence of a potential cross-talk between CaSR 
and TRPC6 in mesangial cells and the impact of long-term clinical use of pharmacological CaSR 
modulators on glomerular function. 
 
In the juxtaglomerular apparatus (JGA) a variety of stimuli lead to renin secretion largely by 
increasing the intracellular cAMP pool19. Acute CaSR activation by calcimimetic inhibits renin 
secretion both in vitro, in mouse primary juxtaglomerular cells, and in vivo20. Furthermore, while a 
rise in intracellular Ca generally promotes exocytosis in secretory cells, in JGA cells an increase in 
extracellular Ca suppresses renin secretion via CaSR-mediated activation of Gq and attendant 
intracellular Ca mobilisation, a phenomenon alluded to as the “calcium paradox”21. In addition, an 
increase in extracellular Ca also leads to suppression of the intracellular cAMP pool by activation 
of calcium-regulated adenylyl cyclases (V and VI) and of phosphodiesterases22. In contrast to what 
observed in acute settings, chronic calcimimetic treatment had no effect on either baseline or 
stimulated plasma renin activityin rats in vivo20. If these observations were to translate to humans 
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they would suggest that long-term treatment with calcimimetics in patients is unlikely to 
significantly affect renin plasma levels. 
 
CaSR in the proximal tubule 
The proximal tubule (PT) plays a crucial role in phosphate transport and PTH, acting on its type 1 
receptor (PTH1R)  is the principal regulator of phosphate reabsorption23. In the PT CaSR is 
expressed apically in the mouse, rat and human kidney 24,13, 25. Furthermore, CaSR expression is 
retained in conditionally immortalized proximal tubular epithelial cell line (ciPTEC) obtained from 
urine of a healthy subject26. Evidence gathered from studies carried out in isolated S3 segments 
suggests that activation of the CaSR directly and rapidly blunts the phosphaturic actions of PTH 
thereby modulating PTH-inhibitable phosphate uptake25. In turn, chronic high dietary Pi intake or 
acute PTH administration suppress proximal tubule CaSR expression27. Furthermore, 1,25(OH)2D3 
increases serum Ca levels by enhancing Ca absorption form the gut and Ca reabsorption from the 
distal convoluted tubule. At the systemic level, these effects are countered by the CaSR via 
suppression of PTH release and increased urinary Ca excretion. In addition, in the human proximal 
tubular cell line HK-8 cells 1-hydroxylation of 25(OH)D3is inhibited by high Ca28 and studies carried 
out in mice lacking both the CaSR and PTH genes show that the CaSR mitigates the calcemic 
response to 1,25(H)2D3  in vivo29. Because these studies were carried out in the context of PTH 
gene deficiency, the authors concluded that the exaggerated calcemic response to 1,25(OH)2D3  in 
the double CaSR/PTH-deficient mice could only be explained by direct, PTH-independent effects of 
the CaSR on the kidney29. In addition, Capasso et al. used both pharmacological (calcimimetic) and 
genetic (CaSR knockout) tools to demonstrate that, in micropuncture experiments in rats in vivo 
and in perfused mouse proximal tubule in vitro, activation of the CaSR by Ca or by calcimimetics 
leads to increased luminal acidification30. The proximal tubule accounts for ~65% of the fluid 
reabsorption via both the transcellular and paracellular routes. NHE3 is crucial to fluid 
reabsorption and to proton secretion. Activation of NHE3 leads to interstitial Na+ accumulation, 
with a local increase in its osmolarity, thereby driving paracellular water reabsorption, hence 
solutes (amongst which, Ca) which are reabsorbed via a process known as “solvent drag”. Because 
CaSR activation in the proximal tubule drives Na transport, which is likely to occur by activation of 
NHE3, this effect would result in an increase in fluid and solutes reabsorption. It is known that PTH 
also induces natriuresis/diuresis by promoting the internalisation of NHE3 and Npt2 via cAMP-
protein kinase A stimulation31. Thus, activation of the apical CaSR could counteract these actions 
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therefore resulting in increased Ca and fluid reabsorption. Overall, these observations suggest 
that, in the proximal tubule, the CaSR directly “fine tunes” PTH actions thereby directly controlling 
Ca and Pi reabsorption, effect which is independent of systemic changes in calciotropic hormones 
(see Figure 1A). These CaSR actions are overridden by systemic changes in serum PTH or Pi, which 
downregulate CaSR expression, selectively by the proximal tubule27. 
 
CaSR in the thick ascending limb 
Approximately 25% of the filtered Ca is reabsorbed in this segment, largely by the cortical TAL 
(CTAL) but also to some extent the medullary TAL (MTAL), a process which is coupled to the 
reabsorption of NaCl32. In this nephron segment PTH stimulates renal tubular calcium reabsorption 
by increasing both the transcellular and paracellular Ca permeability8, 33. In the CTAL an increase in 
peritubular Ca suppresses PTH-induced increase in intracellular cAMP34. CaSR activation in the 
CTAL also decreases hormone (calcitonin, glucagon, vasopressin)-stimulated intracellular cAMP 
accumulation by inhibiting AC635. Paracellular Ca permeability is reliant upon the uptake of NaCl 
across the luminal membrane of this segment which occurs via the bumetanide-sensitive, 
Na/K/2Cl cotransporter (NKCC2). Potassium ions (K) brought into the cell by NKCC2 are recycled 
back into the lumen through an apical, 70 pS renal outer medulla K channels. Intracellular Na and 
Cl are extruded basolaterally via the Na-K-ATPase and voltage-gated Cl channels (CLCNKB)37. 
Together, these processes establish a lumen positive transepithelial potential difference, which 
provides the driving force for passive (ie., without the need for further energy expenditure) 
reabsorption of monovalent and divalent cations (Na, Ca and Mg ions) via the paracellular route.  
In the TAL, the 70-pS channel is formed by ROMK2 and yet-to-be identified subunit(s); ROMK2 
encodes a 30-pS channel36. An increase in peritubular Ca (or Mg) activates the CaSR, located 
basolaterally in this nephron segment, which, in rat microdissected TALs,  directly inhibits the 70 
pS apical K channels via cytochrome p450 and increase in 20-hydroxyeicosatetraenoic acid (20-
HETE) production38 (Figure 1B). Whether CaSR activation also leads to inhibition of the other apical 
K entry via the 30 pS ROMK2 is currently unknown.  Because K recycling is the rate-limiting step for 
NKCC2 activity, such an effect would be expected to result in an abrogation of the driving force for 
paracellular cation reabsorption. In addition, in isolated rat kindey TALs CaSR activation inhibits 
the basolateral 50-pS K channels, consistent with Kir4.1, an effect which results in an inhibition of 
basolateral K recycling, hence of transepithelial cation transport39. However, evidence that such a 
mechanism occurs in vivo is still lacking. Furthermore, direct CaSR effects on the paracellular 
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permeability have also been postulated since calcimimetics and calcilytics affect PTH-stimulated 
Ca reabsorption in the absence of changes in the transepithelial membrane potential40 (see 
below). In any event, hypercalcemia-mediated polyuria (diabetes insipidus) mimicks the effects of 
loop diuretics, which target NKCC2, yielding a “Bartter-like” phenotype with hypokalemia, 
hyperreninemia with secondary hyperaldosteronism and metabolic alkalosis41. Indeed, Bartter 
syndrome (type 5) can also be present in in a subset of individuals with autosomal dominant 
hypocalcemia with hypercalciuria due to activating CaSR mutations42, and that shares many of the 
phenotypic hallmarks of Bartter type 1 and 2, which are caused by mutations in the genes 
encoding NKCC2 and ROMK, respectively (see Figure 1B)43, 44. 
 
CaSR regulates paracellular permeability by the thick ascending limb 
A combination of tissue-specific gene ablation and pharmacological studies, together with 
observations in subjects carrying activating or inactivating mutations in the CaSR gene 
unanimously reveal the primary role for the CaSR renal in the control of urinary Ca excretion 
(reviewed by 40). 
In the TAL, the paracellular permeability is controlled by tight junctional proteins called claudins, 
namely claudin-14, -16, and -19, all of which are linked to hypercalciuria, nephrolithiasis and 
reduced bone mineral density in humans9-11. Claudin-16 and -19 heterodimerise to form the pore 
through which divalent cations are reabsorbed, and whose gating is controlled by claudin-14. 
Claudin-14 expression is increased by high dietary Ca intake and by calcimimetic treatment in vivo 
resulting in decreased paracellular divalent cation permeability45. Recent studies by Hou et al have 
demonstrated that claudin 14 in the TAL is downstream of CaSR activation via the calcineurin-
nuclear factor of activated T cell-microRNA (NFATc1-miR) and chromatin remodelling. Specifically, 
CaSR controls the transcription of miR-9 and miR-374 that target the 3’-untranslated region of the 
claudin-14 gene11. The calcineurin inhibitor, cyclosporine, prevents CaSR-dependent regulation of 
claudin-14 and urinary Ca excretion11 (Figure 1B). While physiologically the CaSR-claudin 14 axis in 
the TAL prevents Ca overload in the presence of elevated serum Ca levels, disturbances in this 
process could contribute to pathological hypercalciuria and nephrocalcinosis (see below). 
Furthermore, studies carried out by Toka et al. using CaSR-specific deletion from the kidney tubule 
demonstate that loss of the renal CaSR results in hypocalciuria which was not accompanied by 
significant changes in serum and urinary Mg excretion 46. Because these mice also show normal 
serum Ca and PTH levels, these studies clearly indicate that the main role of the renal CaSR is to 
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inhibit Ca reabsorption in a PTH-independent fashion. This effect  is accounted for, at least in part, 
by an increase in the paracellular pathway, as evidenced by the concomitant downregulation 
claudin-14 and of NKCC2 activation in these mice. 
Thus, calcimimetic drugs would be expected to increase urinary Ca output via PTH-dependent and 
PTH-independent (renal CaSR-mediated) actions, hence potentially increasing the risk of Ca stone 
occurrence. While it is known that single dose of calcimimetic increases urinary Ca exretion in 
renal transplant patients with secondary hyperparathyroidism47 and that clinical use of 
calcimimetics does not appear to elicit polyuria or renal Na wasting, the impact of calcimimetics or 
calcilytics on nephrolethiasis remains to be investigated.  
 
 
CaSR in the distal convoluted tubule and collecting duct 
The DCT is a short segment which plays a key role for fine-tuning calcium and magnesium 
reabsorption. Apical Ca reabsorption occurs through the calcium channel transient receptor 
potential vanilloid member 5 (TRPV5), and is transported across the basolateral membrane by the 
calcium ATPase (PMCA) and a Na/Ca exchanger (NCX)48, 49. In this nephron segment PTH stimulates 
transcellular calcium reabsorption by cAMP-mediated activation of TRPV548 (Figure 1C). Previous 
studies reported that the CaSR is expressed on the basolateral membrane and in the apical surface 
and in vesicles associated with TRPV524, 50-52, findings confirmed by Graca et al13. Interestingly, 
Topala and co-workers demonstrated that, in HEK293 cells stably transfected with the human 
CaSR, activation of this receptor increases calcium reabsorption via TRPV550. Because in the TAL 
Na and Ca reabsorption are largely associated, a natriuretic stimulus would be expected to 
increase Ca delivery to the DCT. The functional interaction between TRPV5 and CaSR would allow 
for removal of Ca from the pro-urine without affecting Na reabsorption, thus minimising renal 
calcium wasting. However this concerted interplay is unlikely to prevent the hypercalciuric effect 
of loop diuretics, or of activating mutations of the CaSR gene. Moreover, the CaSR has been shown 
to interact with the K channel Kir4.1 expressed on the basolateral membrane of DCT. This 
interaction with Kir4.1 causes its inactivation which in turn could reduce K recycling through the 
basolateral Na-K-ATPase thereby contributing to the inhibition of Na reabsorption in this 
segment51 (Figure 1C). 
 
In the collecting duct the CaSR shows decreasing expression for the cortex to the medulla12, 13. In 
the cortical CD is expressed in intecalated cells as well as in principal cells12, 13 (Figure 1D). In 
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intercalated cells CaSR display a predominant apical distribution and it has been suggested that, in 
dissected mouse outer medullary collecting ducts, its activation by high extracellular Ca promotes 
urine acidification by the stimulation of the luminal H+-ATPase53. Evidence suggests that formation 
of less acidic urine predisposes to urolithiasis54, 55. Of note, TRPV5 _/_ mice are hypercalciuric and 
polyuric with increased urinary acid excretion, but they do not develop renal calcification because 
they exhibit significant urine acidification53. However, when acidification is prevented by targeted 
gene ablation of the collecting duct-specific B1 subunit of the renal H+-ATPase in TRPV5 -/- mice 
significant tubular precipitation of calcium phosphase crystals was observed and animals died 
prematurely of hydronephrosis likely due to the presence of renal stones. In the collecting duct 
principal cells CaSR is localized on the apical membrane and co-localized with AQP2 in intracellular 
vesicles12, 56, 57 where several lines of evidence from in vitro studies, from animal models in vivo 
and from observations in humans suggest that CaSR signaling inhibits vasopressin-induced 
trafficking and expression of the aquaporin-2 (AQP2) water channel58-66. The postulated 
mechanism implies that, under vasopressin action promoting water reabsorption from the lumen, 
an increase in urinary Ca concentration, due to urine concentration, activates the CaSR located on 
the apical membrane of collecting duct principal cells. This activation reduces the vasopressin-
stimulated insertion of AQP2, and in turn the rate of water reabsorption, leading to the formation 
of more dilute urine thereby reducing the risk of calcium supersaturation61, 64, 67. More recently, 
observations carried out in renal cells and microdissected collecting duct demonstrate that the 
inhibitory effect of CaSR signaling on AQP2 trafficking to the plasma membrane is mainly due to a 
strong reduction in cAMP-induced AQP2-pS256 phosphorylation and trafficking with the 
physiological consequence of blunting the osmotic water permeability response65. Further studies 
are necessary to determine the relevance of the CaR-AQP2 interplay in humans and the possibility 
of using CaSR modulators to rectify severe hypercalciuria and nephrocalcinosis68.  
Table 2 summarizes the principal evidence of reported effect of extracellular Ca or calcimimetics 
(either luminal o basolateral) on the renal physiology, thought to be mediated  by CaSR. 
 
Inhibition of hormone-dependent cAMP accumulation by Ca: role of CaSR and AC6 co-expression 
Evidence that the CaSR and the calcium-inhibitable AC6 are co-expressed in the same cells in 
defined nephron segments has led to the hypothesis of a functional interplay of CaSR signaling on 
the inhibition of intracellular cAMP content in response to an increase in extracellular Ca. 
Specifically, functional expression of the AC6 has been demonstrated in the juxtaglomerular cells 
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18,  in the proximal tubule69, in the TAL and in the collecting duct70.  
As discussed previously, by antagonizing the effects of PTH in the kidney, CaSR signaling affects Ca 
and Pi metabolism and regulates tubular transport of Mg, Na, K, Cl and water excretion40. 
As discussed, in the kidney  CaSR signaling affects Ca and Pi metabolism by antagonizing the 
effects of PTH on their tubular transport and tubular regulation of Ca, Mg, Na, K, Cl and water40. 
These effects are modulated by the action of distinct hormones acting on the selected tubular 
segments where the CaSR is expressed. Previous observations demonstrated that, in renal 
epithelial cells, CaSR activation by an increase in extracellular Ca (as well modulation of its 
function by pH and nutrients) results in modulation of intracellular cAMP levels 35,65,71 suggesting 
the possibility that the CaSR converts an extracellular Ca stimulus into a negative feedback on Gs-
linked hormones acting via cAMP.  Based on the observation that CaSR and AC6 are co-expressed 
in the same cells in defined nephron segments, it can be speculated that the negative feedback of 
CaSR on hormones acting through the Gs/AC6/cAMP pathway confers high sensitivity of hormone 
effects to changes in Ca. 
 
CaSR is expressed in renal juxtaglomerular cells and its activation stimulates inctracellular Ca-
mediated decreases in cAMP content and inhibition of renin release through activation of AC5 and 
AC622, 72. 
In the proximal tubule Fenton and coworkers have shown that PTH increases Pi excretion by 
stimulating internalization of the sodium-dependent phosphate transporters (Npt2a and Npt2c) 
from the apical plasma membrane via activation of the AC6 through PTH type 1 receptors 
associated to the cAMP/protein kinaseA signaling pathway69. Evidence that AC6 is the isoform 
mediating this effect was based on data derived from AC6 -/- mice which displayed Pi wasting and 
no response to PTH in terms of phosphate excretion and urinary cAMP excretion69. The authors 
concluded that AC6 in the proximal tubule modulates acute PTH-stimulated cAMP formation and 
urinary Pi excretion. In this scenario CaSR in the proximal tubule can represent a major regulator 
of the PTH action by antagonizing its effects on Pi excretion through downregulation of the 
Gs/AC6/cAMP pathway  (see Figures 1A and 2). 
 
As stated above, in the TAL the main function of CaSR is the regulation of urinary Ca excretion 
having a crucial impact on calcium balance. In this nephron segment NKCC2 and ROMK working in 
concert establish a lumen-positive transepithelial potential differences allowing Ca reabsorption 
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via the paracellular pathway. NKCC2 trafficking and activity is positively regulated by 
phosphorylation at ser126 under vasopressin action73, 74. Interestingly, observations carried out in 
AC6 knockout mice identified AC6 as the isoform mediating the vasopressin-induced 
phosphorylation of NKCC270. The authors found that, in AC6 knockout mice, phosphorylation of 
NKCC2 at ser126 in the medullary portion of the TAL was lacking70.  
Moreover previous evidence in microdissected cortical TAL showed that CaSR and AC6  are 
coexpressed within the same cells and that activation of CaSR by extracellular Ca induced a dose-
dependent inhibition of intracellular cAMP content resulting from both stimulation of cAMP 
hydrolysis and inhibition of cAMP synthesis35.  
This effect on intracellular cAMP associated to CaSR signaling in the TAL indicates that CaSR  
activation impairs vasopressin action in this nephron segment causing changes in transepithelial 
potential due to changes in ion transport as well as to a direct control of components of the tight 
junction proteins including claudins. Using a similar signal transduction pathway, the CaSR is 
expected to counteract PTH-induced Ca reabsortion in TAL. Overall, antagonizing vasopressin and 
PTH action through impairment of the Gs/AC6/cAMP pathway results in reduced Ca reabsorption 
and increase in Ca excretion (see Figures 1B and 2). 
 
The collecting duct represents the nephron segment defining the final composition of urine fine-
tuning electrolytes and water reabsorption. Although little Ca is transported in this segment, the 
extent of water reabsorption and the urine acidification can deeply modify Ca solubility and 
therefore the risk of Ca stone formation. Both AC3 and AC6 are expressed in collecting duct 
principal cells and have both been suggested to contribute to the overall rise in cAMP during 
vasopressin stimulation75. However, several line of evidence suggest that the calcium–inhibitable 
AC6 type is the major enzyme in modulating vasopressin-regulated water reabsorption76-78. 
Collecting duct-specific knockout of AC6 results in a urinary concentration defect associated with 
reduced vasopressin-stimulated cAMP accumulation79. Therefore in the collecting duct Ca 
“sensing” by the CaSR may sensitize vasopressin to luminal Ca resulting in attenuation of the 
antidiuretic response to limit water reabsorption (see Figures 1D and 2). In line with this view, 
data from renal cells and microdissected collecting duct demonstrated that the negative feedback 
of CaSR signaling on vasopressin action are primarily due to reduction of hormone dependent 
cAMP generation and possibly hydrolysis65.  
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Overall, the emerging concept is that within the nephron, co-expression of CaSR and the Ca 
inhibitable AC6 isoform elicits a negative feedback on those hormones acting through the 
Gs/AC6/cAMP pathway, conferring high sensitivity of hormone effects to extracellular Ca 
concentration. This negative feedback mainly relies on inhibition of intracellular cAMP levels as a 
result of CaSR activation by extracellular Ca and consequent inhibition of cAMP synthesis by the Ca 
inhibitable AC6 isoform (Figure 2). 
 
Genetic polymorphisms associated with calcium nephrolithiasis 
CaSR and claudin-14 as two important loci for kidney stone diseases 
As discussed above, CaSR expressed in the TAL inhibits paracellular Ca reabsorption through the 
paracellular pathway by blocking claudin-16 via activation of claudin-14 transcription9.  In the TAL, 
CaSR also decreases the NKCC2 activity that sustains the electrochemical gradient driving the 
paracellular Ca reabsorption45. Therefore CaSR activation by serum Ca in the TAL promotes 
calciuria. On the other hand, in the proximal tubule, CaSR activation antagonises the phosphaturic 
action of PTH and promotes proton secretion through the NHE325, 30 whereas in the collecting duct 
CaSR activation decreases water reabsorption by inhibiting the tubular response to vasopressin 
and increases proton excretion by stimulating proton pump activity. Therefore, CaSR activity in the 
proximal tubule and collecting duct may counterbalance the risk of calcium phosphate 
precipitation associated to the effect of CaSR to enhance Ca excretion in TAL. 
Based on these findings both CaSR and claudin-14 have been investigated as two important loci 
for kidney stone diseases.  Indeed, allelic CaSR variants as well as the tight junctional protein, 
claudin 14, show association with nephrolithiasis80-85. 
The possible involvement of the CaSR in the pathophysiology of calcium nephrolithiasis has been 
investigated by several groups with contrasting results. In a cohort of French patients with familial 
calcium nephrolithiasis86 as well as in a large group of Canadian brothers87 no evidence for 
mutations in the CaSR gene predisposing to the risk of renal stones has been observed. However, 
other groups showed that single-nucleotide polymorphisms (SNPs) of the CaSR are associated with 
nephrolithiasis and kidney stones in patients.  An association between the R990G polymorphism 
of the CaSR gene and primary hypercalciuria was found to be more frequent in hypercalciuric 
calcium stone-forming patients, compared to normocalciuric stone formers or healthy individuals. 
In line with these findings, in vitro data indicated  that R990G polymorphism results in a gain-of-
function of the CaSR88. Other investigators however found no association between this CaSR 
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Arg990Gly polymorphism and indices of serum Ca homeostasis89. 
Calcium nephrolithiasis was also found to be associated with the rs6776158 SNP, located within 
CaSR gene promoter 190. In vitro studies showed that the minor G allele at rs67780158 caused a 
decrease in the transcriptional efficiency of the promoter 1 in two renal cell models90. Moreover 
recent data showed that the simultaneous presence of both rs1501899 and Arg990Gly may 
potentiate the kidney stone risk in patients with primary hyperparathyroidism despite their 
apparently opposite effects on CASR function in the kidney91.  
Regarding the molecular basis of the pathophysiology of calcium nephrolithiasis of the gain-of-
function  Arg990Gly polymorphism, the increase in calcium excretion is expected to predispose to 
intratubular precipitation of calcium-phosphate crystals.  
Conversely, the CaSR polymorphisms rs6776158 SNP at the regulatory region associated with 
decreased CaSR expression may improve the tubular efficency to reabsorb Ca. This may lead to 
increased Ca concentration in the interstitium predisposing to hydroxyapatite precipitation in the 
Randall’s plaque followed by precipitation of urinary calcium oxalate and formation of calcium-
oxalate stones.  Deficient expression may also impair CaSR-associated urine acidification and 
dilution in collecting ducts and phosphate retention in proximal tubules exposing patients to the 
risk of calcium phosphate precipitation in the tubular fluid.  
Based on this evidence, some CaSR polymorphisms may be included amongst factors predisposing 
to stones and can potentially represent a marker to identify patients who may develop calcium 
nephrolithiasis. 
 
Claudins are key components of the paracellular pathway. Studies on the physiological function of 
claudins highlighted a functional interaction between CaSR signaling and claudin gene expression, 
suggesting a role for claudins in nephrolithiasis. Indeed, defects in the function of claudins, have 
been implicated in hypercalciuria and nephrolithiasis (see Hou, 2013 for review84).  
Physiologically, in the thick ascending limb, the claudin 16 channel provides cation permeability to 
the tight junction essential for Ca and Mg reabsorption driven by the lumen-positive 
transepithelial potential gradient. On the other hand, claudin 14 blocks the paracellular cation 
channel made of claudin 16 and claudin 19. The recent demonstration that stimulation of CaSR 
signaling in the TAL downregulates miR-9 and miR-374 causing increasing in claudin 14 levels, and 
in turn suppressing claudin 16 and 19 permeabilities, thus promoting Ca excretion, strongly 
support a role for claudins in nephrolithiasis84. 
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Conclusions and Implications of the latest work and future directions 
Recent studies confirm that the CaSR is expressed all along the nephron, from glomerulus to the 
inner medullary collecting ducts. However, significant differences in its expression levels can be 
found, with the highest expression being in the TAL and the lowest in the glomerulus and proximal 
tubule. Accordingly, direct roles for the CaSR in the kidney have been identified and appear to 
correlate with the expression levels of this receptor. In the TAL the CaSR is a major determinant of 
urinary Ca excretion. In other regions the CaSR appears to “fine-tune” and integrate multiple 
stimuli deriving from Na, pH and mineral ion metabolism, particularly setting the sensitivity 
threshold for several cAMP-coupled hormones to extracellular Ca.  
 
CaSR can be the target for therapeutic intervention for a number of inherited and acquired 
conditions in which the level of expression and/or function of theCaSR is altered (see Box 1). 
Calcimimetics have been proven to be effective in primary and secondary hyperparathyroidism. 
Conversely calcilytics might be used in the future to treat hypoparathyroidism and, in 
hypercalciuric stone-former patients, to prevent nephrolithiasis and nephrocalcinosis. The long-
term use of these modulators on these, and other aspects of renal function modulated by the 
CaSR remains to be evaluated. 
 
 
Key points 
 
 Tissue-specific CaSR ablation and pharmacological studies reveal a pivotal role for the renal 
CaSR in the control of divalent cation excretion, in a PTH-independent fashion 
 CaSR, acting on claudin-14 in the TAL, regulates paracellular Ca reabsorption 
 In other nephron segments the CaSR “fine tunes” Ca, Mg and Pi transport by integrating 
multiple inputs from divalent cation concentration, osmolarity and urine acidification. 
 Calcimimetics would be expected to increase urinary Ca excretion by acting on the CaSR in 
the parathyroid glands and the kidney  
 Calcilytics represent a novel, promising avenue for the treatment of hypercalciuria, 
nephrolithiasis and nephrocalcinosis  
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 Co-expression of CaSR and the calcium-inhibitable AC6 in the nephron sensitises hormones 
to extracellular calcium and counteracts hormone-induced increase in cAMP  
 
Display items 
 
Box 1. Pros and cons of allosteric modulators of the CaSR 
 
Calcimimetics and calcilytics are drugs which act on the CaSR. Calcimimetics enhance CaSR 
sensitivity to extracellular Ca and reduce serum PTH by activating the parathyroid and kidney 
CaSR. Two kinds of calcimimetics have been developed: “type I” calcimimetics are inorganic or 
organic polycationic agonists, and “type II” calcimimetics are positive allosteric enhancers of CaSR 
activity. Cinacalcet is a type II calcimimetic which has been approved to treat advanced secondary 
hyperparathyroidism, an important complication of end-stage chronic kidney disease. Conversely 
calcilytics are allosteric antagonists of the CaSR. They evoke a rightward shift in the Ca 
concentration-response curve at the CaSR, hence higher then normal calcium levels are required 
to suppress PTH release. Owing to their abillity to evoke oscillating fluctuations in serum PTH, a 
known bone anabolic stimulus, calcilytics such as ronacaleret92 and JTT-305/encaleret93 were 
initially developed to treat age-related osteoporosis. While their development has been halted 
due to lack of efficacy, they could be repurposed to treat hypercalciuric disorders due to an 
overactive CaSR.  
Since the CaSR is expressed in a multiplicity of tissues, the potential adverse effects of systemic 
CaSR allosteric modulators cannot be ignored. As an example, cinacalcet normalizes serum PTH 
and calcium concentrations in kidney transplant recipients, however long-term treatment with 
cinacalcet may increase urinary calcium excretion and the risk of renal calcium deposits and may 
alter renal graft function. 
Conversely, calcilytics, expected to reduce urinary calcium excretion, might be used to treat gain-
of-function variants of the CaSR associated with hypercalciuria and stone diseases. However, an 
undesired effect would be to stimulate PTH release, which may worsen the hypercalciuria.  
Development of drugs with tissue-specific action able to modulates differentially specific CaSR-
regulated processes, particularly in the setting of an under-active or over-active CaSR, is the future 
challenge in CaSR drug discovery. 
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Figure Legends 
 
Figure 1. Schematic representation of the CaSR in the kidney tubule 
A) CaSR in the proximal tubule. The CaSR blunts the phosphaturric action of PTH, inhibits the 
activity of CYP27B1 (1-hydroxylase), promotes acidification via NHE3 which in turns drives Na 
accumultion in the interstitium and solute reabsorption. B) CaSR in the TAL. Hypercalcemia 
activates the CaSR in the TAL leading to an inhibition of ROMK channel, thereby prevening apical K 
recycling, the rate-limiting step for NKCC2 activity, leading to loss of the driving force for 
paracellular cation reabsorption. Thus, hypercalcemia mimicks the effects of loop diuretics and 
recapitulates a Bartter type 1 and 2 phenotypes, ascribed to mutations in the genes encoding  
NKCC2 or ROMK, respectively, an effect which is also mimicked by activating mutatins in the CaSR 
gene (Bartter type 5) with hypercalciuria, hypokalemic alkalosis and hyperreninemic 
hyperaldosteronism. Bartter type 3 and 4 are due to mutations in the genes encoding the 
basolateral Cl channel, ClC-Kb or its auxiliary subunit, Barttin, respectively. CaSR activation also 
directly regulates paracellular permeability via NFATc1-microRNA-Cldn-14. C) CaSR in the DCT. At 
the apical membrane CaSR is biochemically associated with the 1,25(OH)2D3-regulated TRPV5. 
Increased Ca delivery (filled circles) to the DCT results in CaSR activation, hence incrased apical Ca 
entry via TRPV5. Intracellularly, calbindin D28K (indicated by crescents) delivers Ca ions are to the 
basolateral membrane where Ca exits the cell via active mechanisms (PMCA and NCX). CaSR also 
decreases surface expression of Kir 4.1 resulting in an inhibition of NaCl reabsorption. D) CaSR in 
the CD. In the presence of an antidiuretic stimulus, Ca concentrations in the pro-urine can become 
supersaturating, potentially leading to Ca stone formation (indicated by stars). When luminal Ca 
concentration becomes critical it activate the apical CaSR which, in principal cells, blunts 
vasopressin-mediated apical insertion of AQP2 water channels and in turn the rate of water 
reabsorption. In intercalated cells CaSR activation leads to luminal acidification. Overall, these two 
effects result in the production of a more dilute, acidified urine, thereby reducing the risk of 
nephrolithiasis.  
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Figure 2. CaSR confers high sensitivity to extracellular calcium concentration by reducing the 
effects of distinct hormones selectively acting in selected nephron segments via Gs/AC6/cAMP 
pathway 
CaSR is expressed in renal juxtaglomerular cells and its activation stimulates calcium-mediated 
decreases in cAMP content and inhibits renin release through activation of AC5 and AC6. 
In the proximal tubule CaSR is expressed on the luminal membrane and its activation impairs PTH 
action by antagonizing its effects on Pi excretion through downregulation of the Gs/AC6/cAMP 
pathway. This reduces Pi excretion limiting the risk of formation of Ca-Pi precipitates. In the thick 
ascending limb CaSR signaling counteracts vasopressin action on activation of NKCC2 
phosphorylation causing changes in transepithelial potential resulting in overall reduced Ca 
reabsorption.  In this segment AC6 is the adenylate cyclase isoform activated by vasopressin. Using 
a similar signal transduction pathway, CaSR is expected to counteract PTH-induced Ca reabsortion 
in TAL.   In the collecting duct, activation of CaSR by luminal calcium reduces the vasopressin-
stimulated insertion of AQP2, leading to the formation of more dilute urine favoring the solubility 
of calcium phosphate salts.  
The negative feedback of CaSR on hormones acting through the Gs/AC6/cAMP pathway is 
principally due to the inhibition of cAMP synthesis by the Ca-inhibitable AC6 as a consequence of 
CaSR-activated increase in intracellular Ca concentration. 
 
Table 1. Summary of CaSR mRNA (in situ hybridisation) and protein (immunohistochemistry and 
proximity ligation assay) expression levels along the nephron. The highest CaSR mRNA and 
protein expression levelswere observed in the TAL while only faint protein expression could be 
osberved in the glomerulus (from: Graca et al, AJP RP, 2015)13.  
 
Table 2.  Reported effects of extracellular Ca (either luminal o basolateral) on the renal physiology, 
believed to be mediated  by CaSR. 
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 Table 1. Summary of CaSR mRNA (in situ hybridisation) and protein (immunohistochemistry and 
proximity ligation assay) expression levels along the nephron. The highest CaSR mRNA and 
protein expression levelswere observed in the TAL while only faint protein expression could be 
osberved in the glomerulus (from: Graca et al, AJP RP, 2015)13.  
 
 Glomerulus PT TAL DCT CNT CCD OMCD/IMCD 
mRNA - + +++ ++ + ++ + 
Protein + + +++ ++ + ++ + 
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Table 2. Reported effects of CaSR activators and inhibitors on renal physiopathology 
 
 
 
 
 
 
 
 
  
Nephron segment Modulated function Experimental model Evidence for specific 
CaSR involvement 
References 
Glomerulus  Regulation of glomerular 
function, possible role in   
preventing 
glomerulosclerosis  
Cultured podocytes;  
toxin-induced 
glomerulosclerosis in rats; 
apolipoprotein E-deficient 
mice 
Type II calcimimetic (R-
568) 
Refs 16-17 
 
Juxtaglomerular apparatus Inhibition of renin 
secretion 
Primary cultures of mouse 
juxtaglomerular cells; in 
vivo experiments in rats 
Type I calcimimetic 
(extracellular Ca) 
Ref 20 
 
Proximal tubule  
(apical) 
Inhibition of  PTH-
dependent phosphate 
uptake 
Microdissected mouse S3 
segments; proximal 
tubule-like opossum 
kidney cells 
Type I calcimimetics (Gd3+ 
/ extracellular Ca) 
Ref 25 
Proximal tubule 
(apical) 
Increase in luminal 
acidification; increase in 
fluid reabsorption 
In vivo micropuncture in 
rats; in vitro perfused 
mouse proximal tubules; 
proximal tubules isolated 
from CaSR knockout mice 
Type II calcimimetic 
(cinacalcet)/type I 
calcimimetic (luminal Ca) 
Ref 30 
 
Thick ascending limb 
(basolateral) 
Inhibition of PTH, 
vasopressin, calcitonin, 
glucagon, actions; 
decrease in Ca absorption. 
 
Dissected mouse TAL; 
dissected rat TAL 
  
 
Type I calcimimetic 
(extracellular Ca)  
Refs 34-35 
 
Thick ascending limb 
(basolateral) 
Control of urinary Ca 
absorption; increased 
expression of Claudin-14  
 
In vivo treatment of mice; 
cell culture models; 
patients with autosomal 
dominant hypocalcemia 
(ADH) due to CaSR 
activating mutations  
Type II calcimimetic 
(cinacalcet); calcilytic 
(NPS2143) 
 
Refs 10; 45 
 
Distal convoluted tubule 
(apical/basolateral) 
Stimulation of Ca 
reabsorption 
Cell culture models 
expressing a “dominant 
negative” CaSR (R185Q) 
Type I calcimimetic 
(neomycin) 
Ref 50 
Collecting duct 
intercalated cells 
(apical) 
Increase in luminal 
acidification 
Dissected mouse outer 
medullary collecting ducts; 
gene ablation of the 
collecting duct-specific B1 
subunit of H(+)-ATPase 
Type I calcimimetic 
(luminal Ca) 
Ref 53 
Collecting duct principal 
cells 
(apical) 
Decrease in AQP2-
mediated water 
reabsorption, inhibition of 
vasopressin response  
Hypercalcemic rats; 
dissected rat kidney inner 
medullary collecting duct; 
cell culture models; 
human bedrest; AQP2 
isolated vesicles; 
hypercalciuric patients 
 
Type I calcimimetics 
(neomycin, 
gadolinium)/type II 
calcimimetic (R-568)  
Type I calcimimetic 
(luminal Ca) 
Refs 56;  58-64 
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